Jupiter Neurosciences highlights improved resveratrol formulation

JUPITER, Florida - Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a $56 million market cap biotech company, announced Wednesday that its proprietary resveratrol platform, JOTROL, has demonstrated significantly higher bioavailability compared to conventional resveratrol formulations. InvestingPro data shows the stock has experienced significant volatility, with shares currently trading at $1.69, down over 84% year-to-date.

According to a company press release, JOTROL achieved a nine-fold increase in bioavailability in a Phase I clinical trial without the gastrointestinal side effects typically associated with high doses of traditional resveratrol.

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, stated that conventional resveratrol products would require approximately 5 grams to reach minimum effective plasma concentration levels, which typically causes severe gastrointestinal issues.

The company reports that JOTROL has secured intellectual property protection in the U.S., EU, China, Japan, and Hong Kong through 2036. The formulation is designed to cross the blood-brain barrier, which the company considers critical for addressing neurological conditions.

Jupiter Neurosciences is advancing JOTROL toward a Phase IIa trial in Parkinson’s Disease following preclinical testing in an MPTP mouse model that showed improvements in motor functions.

The company also plans to launch a consumer product line called Nugevia in the third quarter of 2025, which will use the same delivery technology as JOTROL.

Jupiter Neurosciences describes itself as pursuing a dual-path strategy addressing neuroinflammation through pharmaceutical development while also entering the consumer market with supplements targeting cognitive health, mitochondrial energy, and skin vitality. InvestingPro analysis reveals 11 additional key insights about the company’s financial health and market position, available to subscribers.

In other recent news, Jupiter Neurosciences has announced several developments. The company has regained compliance with Nasdaq’s minimum share price requirement, as confirmed by Nasdaq’s Listing Qualifications Department. This follows a period where its common stock maintained an average closing share price of at least $1.00 for 13 consecutive trading days. Additionally, Jupiter Neurosciences’ board approved a bonus package for key executives, which includes stock options and cash payments. This decision came after a review of the company’s final 2025 budget and acknowledges the executives’ contributions to the initial public offering in December 2024.

Jupiter Neurosciences is also expanding its product offerings with the upcoming launch of two new supplements this fall. Nugevia PWR, a mitochondrial health supplement, is designed to support cellular energy and endurance. The company will also release Nugevia GLO, a skin health supplement that combines their proprietary JOTROL technology with NovaSOL Astaxanthin. Furthermore, the company has launched Nugevia, a new product line aimed at enhancing longevity, which marks a strategic move to create immediate revenue streams.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.